The invention relates to the compounds of ##STR00001##
related compounds, or pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

The invention relates to the compounds of ##STR00001##
related compounds, or pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

Improved methods for preparing chemical precursors to sulfonyl chloride III, which are important intermediates in the preparation of pyroxsulam herbicide are provided. Specifically, these precursors are compounds of Formulas VII and/or VIII, and IX, wherein R is a C.sub.1-C.sub.6 alkyl, R.sup.1 is a C.sub.1-C.sub.6 alkyl, X is Cl or OH, Y is halogen, OH, or OR.sup.2, and R.sup.2 is a C.sub.1-C.sub.6 alkyl.

##STR00001##

Improved methods for preparing chemical precursors to sulfonyl chloride III, which are important intermediates in the preparation of pyroxsulam herbicide are provided. Specifically, these precursors are compounds of Formulas VII and/or VIII, and IX, wherein R is a C.sub.1-C.sub.6 alkyl, R.sup.1 is a C.sub.1-C.sub.6 alkyl, X is Cl or OH, Y is halogen, OH, or OR.sup.2, and R.sup.2 is a C.sub.1-C.sub.6 alkyl.

##STR00001##

Ocular lenses having UV absorbing properties are disclosed. The ocular lens comprises a hydrogel polymer comprising polymerised residues derived from a polymerisable UV absorber of formula (I):

U-L-Py  (I)

wherein: U is a UV absorbing moiety; L is a hydrophilic non-polyalkylene glycol linker comprising an anionic, a zwitterionic or a saccharide moiety; and Py is an ethylenically unsaturated polymerisable moiety.

Ocular lenses having UV absorbing properties are disclosed. The ocular lens comprises a hydrogel polymer comprising polymerised residues derived from a polymerisable UV absorber of formula (I):

U-L-Py  (I)

wherein: U is a UV absorbing moiety; L is a hydrophilic non-polyalkylene glycol linker comprising an anionic, a zwitterionic or a saccharide moiety; and Py is an ethylenically unsaturated polymerisable moiety.

This disclosure concerns a method of making a ligand for Quantum Dot functionalization, a method of making a functionalized Quantum Dot (QD) with a ligand, and a method of making a transparent luminescent quantum dot thiol-yne nanocomposite with tailorable optical, thermal, and mechanical properties. The prepolymer solution and functionalized Quantum Dot can be used in additive manufacturing.

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).

##STR00001##